The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting (CINV) following repeated chemotherapy cycles: Results of a phase III trial.
Karin Jordan
Consultant or Advisory Role - Helsinn Therapeutics; Merck
Honoraria - Helsinn Therapeutics; Merck KGaA
Giorgia Rossi
Employment or Leadership Position - Helsinn Therapeutics
Giada Rizzi
Employment or Leadership Position - Helsinn Therapeutics
Marco Palmas
Employment or Leadership Position - Helsinn Therapeutics
Richard J. Gralla
Consultant or Advisory Role - Helsinn Therapeutics
Honoraria - Helsinn Therapeutics